By Stephen Nakrosis
Shares of Serina Therapeutics advanced in the after-hours market after the company said it closed on a $5 million tranche of equity financing.
The stock rose 6.5% to $5.23 post-market, adding to the 4.4% gain seen in regular session that saw shares close at $4.91.
The company said it successfully closed the second tranche of a total $10 million equity financing agreement with strategic shareholder JuvVentures (UK).
Serina said the proceeds will be used to continue advancing its SER-252, or POZ-apomorphine, into a Phase 1 clinical trial in advanced Parkinson's disease patients in the second half of this year.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
February 03, 2025 17:59 ET (22:59 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.